CA
NZ
UK
AU
IND
US
Lakeland Industries, Inc. (NASDAQ: LAKE) generated $50.1 million in net sales for the fiscal second quarter ended July 31, 2026. The company recorded a $4.9 million net loss and $2.7 million of adjusted EBITDA excluding foreign exchange. Fire and Fire Services provided momentum, while …
The planned capability is designed to intercept hostile drones before they reach protected platforms, extending vehicle protection beyond armor and electronic countermeasures.
Vaxcyte, Inc. (NASDAQ: PCVX) awarded Chief Medical Officer Jodar Luis 52,632 shares at $0 per share. The award was recorded on Sep 4, 2026, and Luis’s resulting holding was 52,632 shares.
TENAX Therapeutics, Inc. (NASDAQ: TENX) released a comprehensive LEVEL clinical-trial update showing a 49% reduction in NT-proBNP, while the study’s primary endpoint did not reach statistical significance. The results update covers the company’s levosimendan development program and was made public on September 9, 2026. …
Tyra Biosciences, Inc. (NASDAQ: TYRA) identified oral dabogratinib at 60 mg once daily as a potential dose for its planned registrational adjuvant strategy in a bladder cancer population with FGFR3 alterations. SURF302 produced an overall response rate of 79%, or 11 of 14 evaluable …
UroGen Pharma Ltd. (NASDAQ: URGN) General Counsel Jason Drew Smith sold 1,519 shares at $42.54 per share on Sep. 8. His share ownership afterward stood at 53,141 shares.
UroGen Pharma Ltd. (NASDAQ: URGN) Chief Medical Officer Mark Schoenberg exercised options for 1,667 shares on Sep 7, leaving him with 60,753 shares. The next day, he sold 871 shares at $42.92 per share, after which his reported holding stood at 59,882 shares.
ProQR Therapeutics N.V. (NASDAQ: PRQR) has dosed the first participant in its AX-0811 clinical study, advancing the RNA editing candidate into testing in healthy volunteers. The study will examine safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers for a potential treatment targeting cholestatic liver diseases, including …
Pyxis Oncology, Inc. (NASDAQ: PYXS) reported updated Phase 1 results for MICVO that support advancing the drug into a key program after a 36% confirmed objective response rate, or 12 of 33 efficacy-evaluable patients. The study evaluated patients with second-line and beyond recurrent or …
QIAGEN N.V. (NYSE: QGEN) appointed Jonathan M. Pratt as chief executive officer effective September 1, 2026, succeeding Thierry Bernard. Bernard also stepped down from the Managing Board on that date, while QIAGEN reaffirmed its third-quarter and full-year 2026 outlook.
Please wait processing your request...